C
BioSyent Inc.
BIOYF
$7.38
$0.253.51%
C
Hold
9/4/2020Upgraded
BioSyent Inc. (BIOYF) was upgraded to C from C- on 9/4/2020 due to an increase in the growth index, volatility index and total return index. Operating cash flow increased 286.97% from $420.5 to $1.63M.
BioSyent Inc. (BIOYF) was upgraded to C from C- on 9/4/2020 due to an increase in the growth index, volatility index and total return index. Operating cash flow increased 286.97% from $420.5 to $1.63M.
C
Hold
8/3/2020Upgraded
BioSyent Inc. (BIOYF) was upgraded to C- from D+ on 8/3/2020 due to a major increase in the growth index, volatility index and efficiency index. Earnings per share increased from $0.0607 to $0.0803, net income increased 22.1% from $884.8 to $1.08M, and total revenue increased 6.94% from $4.22M to $4.51M.
BioSyent Inc. (BIOYF) was upgraded to C- from D+ on 8/3/2020 due to a major increase in the growth index, volatility index and efficiency index. Earnings per share increased from $0.0607 to $0.0803, net income increased 22.1% from $884.8 to $1.08M, and total revenue increased 6.94% from $4.22M to $4.51M.
D
Sell
3/20/2020Downgrade
BioSyent Inc. (BIOYF) was downgraded to D+ from C- on 3/20/2020 due to a significant decline in the growth index, volatility index and valuation index. EBIT declined 38.85% from $1.41M to $860.7, earnings per share declined from $0.0833 to $0.0606, and total revenue declined 10.43% from $4.71M to $4.22M.
BioSyent Inc. (BIOYF) was downgraded to D+ from C- on 3/20/2020 due to a significant decline in the growth index, volatility index and valuation index. EBIT declined 38.85% from $1.41M to $860.7, earnings per share declined from $0.0833 to $0.0606, and total revenue declined 10.43% from $4.71M to $4.22M.
C
Hold
3/18/2020Upgraded
BioSyent Inc. (BIOYF) was upgraded to C- from D+ on 3/18/2020 due to a noticeable increase in the valuation index and volatility index.
BioSyent Inc. (BIOYF) was upgraded to C- from D+ on 3/18/2020 due to a noticeable increase in the valuation index and volatility index.
D
Sell
2/12/2020Downgrade
BioSyent Inc. (BIOYF) was downgraded to D+ from C- on 2/12/2020 due to a decline in the volatility index, efficiency index and growth index.
BioSyent Inc. (BIOYF) was downgraded to D+ from C- on 2/12/2020 due to a decline in the volatility index, efficiency index and growth index.
C
Hold
12/9/2019Upgraded
BioSyent Inc. (BIOYF) was upgraded to C- from D+ on 12/9/2019 due to a substantial increase in the growth index, valuation index and volatility index. Operating cash flow increased 184.31% from $383.6 to $1.09M, earnings per share increased from $0.0367 to $0.0833, and EBIT increased 52.11% from $925.3 to $1.41M.
BioSyent Inc. (BIOYF) was upgraded to C- from D+ on 12/9/2019 due to a substantial increase in the growth index, valuation index and volatility index. Operating cash flow increased 184.31% from $383.6 to $1.09M, earnings per share increased from $0.0367 to $0.0833, and EBIT increased 52.11% from $925.3 to $1.41M.
D
Sell
8/27/2019Downgrade
BioSyent Inc. (BIOYF) was downgraded to D+ from C- on 8/27/2019 due to a decline in the total return index, growth index and valuation index. EBIT declined 30.09% from $869.3 to $607.7, and earnings per share declined from $0.0512 to $0.0374.
BioSyent Inc. (BIOYF) was downgraded to D+ from C- on 8/27/2019 due to a decline in the total return index, growth index and valuation index. EBIT declined 30.09% from $869.3 to $607.7, and earnings per share declined from $0.0512 to $0.0374.
C
Hold
6/13/2019Downgrade
BioSyent Inc. (BIOYF) was downgraded to C- from C on 6/13/2019 due to a large decline in the growth index, total return index and volatility index. Operating cash flow declined 108.85% from $2.05M to -$181.8, EBIT declined 44.45% from $1.56M to $869.3, and earnings per share declined from $0.0833 to $0.0512.
BioSyent Inc. (BIOYF) was downgraded to C- from C on 6/13/2019 due to a large decline in the growth index, total return index and volatility index. Operating cash flow declined 108.85% from $2.05M to -$181.8, EBIT declined 44.45% from $1.56M to $869.3, and earnings per share declined from $0.0833 to $0.0512.
C
Hold
3/11/2016Downgrade
BioSyent Inc. (BIOYF) was downgraded to C from B+ on 3/11/2016 due to a significant decline in the volatility index, growth index and total return index. Earnings per share declined from $0.0611 to $0.0374, operating cash flow declined 26.5% from $1.41M to $1.04M, and EBIT declined 20.53% from $1.22M to $970.
BioSyent Inc. (BIOYF) was downgraded to C from B+ on 3/11/2016 due to a significant decline in the volatility index, growth index and total return index. Earnings per share declined from $0.0611 to $0.0374, operating cash flow declined 26.5% from $1.41M to $1.04M, and EBIT declined 20.53% from $1.22M to $970.
B
Buy
1/15/2016Downgrade
BioSyent Inc. (BIOYF) was downgraded to B+ from A- on 1/15/2016 due to a large decline in the total return index.
BioSyent Inc. (BIOYF) was downgraded to B+ from A- on 1/15/2016 due to a large decline in the total return index.
A
Buy
12/31/2015Upgraded
BioSyent Inc. (BIOYF) was upgraded to A- from B+ on 12/31/2015 due to a noticeable increase in the total return index, growth index and valuation index. Operating cash flow increased 111.05% from $670.4 to $1.41M, EBIT increased 29.99% from $939 to $1.22M, and earnings per share increased from $0.0488 to $0.0611.
BioSyent Inc. (BIOYF) was upgraded to A- from B+ on 12/31/2015 due to a noticeable increase in the total return index, growth index and valuation index. Operating cash flow increased 111.05% from $670.4 to $1.41M, EBIT increased 29.99% from $939 to $1.22M, and earnings per share increased from $0.0488 to $0.0611.
B
Buy
7/1/2015Upgraded
BioSyent Inc. (BIOYF) was upgraded to B+ from B on 7/1/2015 due to an increase in the valuation index and growth index. Earnings per share increased from $0.0439 to $0.056, and EBIT increased 14.09% from $920.4 to $1.05M.
BioSyent Inc. (BIOYF) was upgraded to B+ from B on 7/1/2015 due to an increase in the valuation index and growth index. Earnings per share increased from $0.0439 to $0.056, and EBIT increased 14.09% from $920.4 to $1.05M.
B
Buy
4/1/2015Upgraded
BioSyent Inc. (BIOYF) was upgraded to B from B- on 4/1/2015 due to an increase in the valuation index, volatility index and solvency index.
BioSyent Inc. (BIOYF) was upgraded to B from B- on 4/1/2015 due to an increase in the valuation index, volatility index and solvency index.
B
Buy
1/2/2015Upgraded
BioSyent Inc. (BIOYF) was upgraded to B- from C on 1/2/2015 due to a substantial increase in the volatility index, growth index and valuation index. Operating cash flow increased 54.29% from $971.7 to $1.5M, total revenue increased 18.4% from $2.82M to $3.34M, and earnings per share increased from $0.055 to $0.0643.
BioSyent Inc. (BIOYF) was upgraded to B- from C on 1/2/2015 due to a substantial increase in the volatility index, growth index and valuation index. Operating cash flow increased 54.29% from $971.7 to $1.5M, total revenue increased 18.4% from $2.82M to $3.34M, and earnings per share increased from $0.055 to $0.0643.
C
Hold
7/1/2014Upgraded
BioSyent Inc. (BIOYF) was upgraded to C from C- on 7/1/2014 due to an increase in the total return index and solvency index. The quick ratio increased from 4.07 to 5.45.
BioSyent Inc. (BIOYF) was upgraded to C from C- on 7/1/2014 due to an increase in the total return index and solvency index. The quick ratio increased from 4.07 to 5.45.
C
Hold
4/1/2014Upgraded
BioSyent Inc. (BIOYF) was upgraded to C- from D+ on 4/1/2014 due to an increase in the solvency index. The quick ratio increased from 3.39 to 4.07.
BioSyent Inc. (BIOYF) was upgraded to C- from D+ on 4/1/2014 due to an increase in the solvency index. The quick ratio increased from 3.39 to 4.07.
OTC PK
04/09/2025 3:58PM Eastern
Quotes delayed
